March 10, 2006—The FDA granted traditional approval status this week to both once-daily Viread and Truvada (a mixture of Viread and Emtriva). This allows drug-maker Gilead to include results on their labels from a new study that found taking Viread and Emtriva more effective and less toxic than Combivir.